Highly potent API manufacturing is a rapidly growing segment of drug development. Those familiar with HPAPI understand its specialized nature and the strict regulations surrounding it. A complicated and resource-intensive process, sponsors often find themselves in need of knowledgeable outsourcing…
Choosing an outsourcing partner for a commercial bioprocessing endeavor carries a gravitas that those outside that endeavor may not appreciate. Equally significant is the challenge facing CMOs in this space, many of whom are competing against larger, well-known manufacturers with…
I bet you can’t say “cell & gene therapies” three times fast. And by the time you do, you’ll have missed another article on your newsfeed discussing their intricacies and the headaches they can cause. Here’s one from Industry Standard…
ISR’s CTMS Benchmarking & Market Dynamics (3rd Ed.) aims to tackle clinical trial management systems (CTMS) by helping providers and sponsors alike better understand current trends surrounding this technology and anticipate future ones. This report is the result of primary…
How do you ensure the research products and services you buy will make you confident in the decisions you make? Here are six reasons why Industry Standard Research ensures you are getting the value you should expect from quality market…
How Pharma, CROs, and CDMOs can prepare for 2020 ISR conducted approximately two dozen individual pieces of market research for syndication in 2019. This webinar summarizes many of the important learnings from these projects, providing attendees with real, usable data…
Vice President of Market Research at Industry Standard Research Rebecca McAvoy discusses whether the company size of a CRO has an impact on its therapeutic expertise, and by extension, an impact on outsourcing selection. CRO selection. Whether you’ve been in…
Informing pharmaceutical drug developers, manufacturers, and service providers Raleigh, N.C. — October 16, 2018 — Industry Standard Research (ISR) announces the release of its newest report, “Phase I Study Trends and Market Outlook (2018-2022),” in which 143 Phase I decision-makers…